Navigation Links
Memphis Hospitals announces debt tender offer
Date:9/7/2007

Methodist Healthcare - Memphis Hospitals Announces Tender Offer for The Health, Educational and Housing Facility Board of the County of Shelby, Tennessee Adjustable-Rate Hospital Revenue Bonds, Series 1985C (Methodist

Health Systems, Inc.) ("Series 1985C Bonds") The Health, Educational and Housing Facility Board of the County of Shelby, Tennessee Hospital Revenue Bonds, Series 1995 (Methodist Health Systems,

Inc.) ("Series 1995 Bonds") The Health, Educational and Housing Facility Board of the County of Shelby,

Tennessee Hospital Revenue Bonds, Series 1998 (Methodist Healthcare) ("Series 1998 Bonds" and, together with Series 1985C Bonds and Series 1995

Bonds, the "Bonds")

MEMPHIS, Tenn., Sept. 7 /PRNewswire/ -- Methodist Healthcare -- Memphis Hospitals ("Methodist") announced today that it has commenced a tender offer (the "Offer") for the Bonds.

Pursuant to the Offer, Methodist would like the holders of these Bonds to tender their Bonds in return for a premium price. The Tender Price for the different maturities of each Series is contained in the Offer. The Series 1985C Bonds and Series 1995 Bonds are currently callable and the Series 1998 Bonds are callable beginning April 1, 2008. The Tender Price, subject to the terms and conditions of the tender offer, is one percent (1%) higher than the redemption price Methodist would need to pay if it were to redeem the Bonds at this time (or on April 1, 2008 in the case of the Series 1998 Bonds).

The Offer will expire at 5:00 P.M., New York City time, on October 10, 2007, unless earlier terminated or extended by Methodist in its sole discretion.

Methodist is a Tennessee non-profit corporation that owns and operates four adult acute-care hospitals in the Memphis, Tennessee area (including Methodist University Hospital, South Hospital, North Hospital, and Germantown Hospital) and one pediatric acute-care hospital
'/>"/>

SOURCE Methodist Hospitals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Apollo Hospitals to consider listing on US Bourses in 2003
2. Greater volume hospitals better for stroke
3. Apollo Hospitals Collaborates With Histostem For Stem Cell Therapy
4. Indian Hospitals – A Destination For Quality Medical Care
5. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
6. Indian hospitals require International Accreditation
7. Quality Awareness In Hospitals Can Reduce Mortality Rate Of Patients
8. First PET-CT guided radiotherapy in India was performed by Apollo Hospitals
9. Delhi Government To Interlink All Major Hospitals Through e-Governance
10. Global Hospitals coming to city of Joy
11. Religious Leaders condemn determination of sex in hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...r Seeks to Raise $38 Million for Life-threatening,...wire/ -- Walkers in nearly,every state will raise ...nd,18 -- by participating in GREAT STRIDES, the la... Foundation announced today., May is National Cys...,life-threatening genetic disease that causes fata...
(Date:5/16/2008)...s is more unemployed politicians - and economists,... Although nearly all,voters place health care at t...oming federal budgetary crunch means none of the h...esidential candidates is likely to become,law anyt...Bill Frist., Jousting with Princeton University H...
(Date:5/16/2008)...PRNewswire-USNewswire/ -- As tropical storms,conti...elta, survivors of,Cyclone Nargis are vulnerable t...rs still need assistance, as exposure to the foul ...gly dire situation., "The people living in these ... this disaster and get back on their feet," said D...
(Date:5/16/2008)...., May 16 /PRNewswire-FirstCall/ -- Nationwide,Hea... the promotion of David,M. Boitano to Senior Vice ... made a tremendous contribution to NHP over the la...ment growth and diversification strategy,successes... accretive,investments for NHP, leveraging his vas...
Breaking Medicine News(10 mins):Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:David M. Boitano Promoted to Senior Vice President 2
...has issued a temporary regulation on human organ t... organ trade, under control // and regulate transp...s regarding organ transplantation and donation wou...y in the best interest of the patients. The new r...
... that lifted up faces and brought cheer to the Chu... tabs for three types of obesity surgery, in case...ms. // But the catch is that, only surgeries perf...ons or the American Society of Bariatric Surgery w...
...irst to chair some healthy practices in classrooms...stand for hours a day. // This follows a study, wh... to significant weight loss, as against sitting wh.... According to researchers, children were capable ...
... in the May 1, 2006 issue of CANCER, a peer-review...t weight training// improves the quality of life o... cancer. A bi-weekly exercise regimen for six mont...tional condition of the patients. In the initial ...
Other Medicine News:Health News:China Issues New Legislation To Ban Human Organ Trade 2Health News:Welcome to ‘Stand Only’ Classrooms That Exercise The Brain And The Bod 2
(Date:5/16/2008)... MicroRNAs as Potential Biomarkers -- for Lung Ca... in Patients With Cancer of Unknown Primary ...tively Identify Cancer Types With High Sensitivity...sis and Treatment of Cancer Results of microRNA S... Accuracy Exceeding 90% and Specificity of...
(Date:5/15/2008)...Trial Results Confirm Efficacy for Population Most...E, Calif., May 16 /-,Bayer ...uticals, Inc.,(Nasdaq: ONXX ) today announced tha...roved overall survival by 47.3 percent (HR=0.68;,p...on with advanced,hepatocellular carcinoma (HCC), o...
(Date:5/15/2008)...- First in human clinical data highlight safety pr...advanced solid tumors -, BRISBANE, Calif., May 15... held biopharmaceutical company developing novel c...ing its lead PARP inhibitor, BSI-201, will,be pres...ology annual,meeting in Chicago., Findings will b...
(Date:5/15/2008)... - Unprecedented amount of research reflects dep...rs worldwide to develop new treatments for ...y session to highlight impact of Zometa(R), the le...nts with early-stage breast cancer, - Four oral s...ontinuous, inhibitor of mTOR, including first resu...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 1Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 6Esperanza Announces Support of H R 1108 Encourages Congress to Pass FDA Regulation of Tobacco 18994 1Human aging gene found in flies 18989 1Human aging gene found in flies 18989 2Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs 3263 1Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs 3263 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 11 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 8.7 mm.
Medicine Products: